Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Review Article and Clinical Experience: Insulin Glargine Combined with Oral Agent in T2DM (Clinical Uses of Formulas: 1/3, 5-5, 2-2, 1-1, and 1-2)

Folia Medica Indonesiana · Vol. 41 No. 3 (2005)

ISSN
2355-8393, 2599-056X
Terbit
2005-07-01
Penerbit
Airlangga University
Bahasa
en

Abstrak

A map of oral agents for diabetes (OADS), either at present or in the future should be well recognized. Four of such OADS (glimepiride, glinides, gliclazide, metformin) have claimed showing atheroprotective properties beyond its hypoglycemic or anti- hypoglycemic effects. On the basis of clinical experiences and molecular mechanisms, glimepiride (GLIM) can be summarized having 3B - 3A - 9D properties 3-fold higher rate of Binding to receptor (3B), 3-fold lower Affinity to receptor (3A), and 9-fold faster rate of Dissociation from receptor (9D). These effects (3B-3A-9D) may result in potential therapeutical benefits, including rapid onset (due to 3-fold higher rate of Binding = 3B) and less hypoglycemic events due to lower Affinity (3A) and faster Dissociation (9D). By using therapeutic concentration (in contrast to glibenclamide), GLIM (via PI3-Kinase Pathway) increases insulin - stimulated glycogen synthesis (GS) in human muscle cells (GS effect). In addition, GLIM inhibits platelet aggregation which may in turn have a preventive effect on the development of diabetic vascular complications (more pronounced effect than gliclazide). The ideal basal insulin should ideally have the following six characteristics 1. mimics normal pancreatic basal insulin secretion, 2. long-lasting 24-hour effect, 3. smooth, peakless profile, 4. reproducible and predictable effects, 5. reduces risk of nocturnal hypoglycemia, and 6. once-daily administration. Insulin Glargine (GLAR) is a novel peakless long-acting insulin analogue that is available for clinical use and it has a smooth profile and long, 24-hour duration of action. Thus, GLAR is an improved basal component for combination regimens (Method A, B, and C) with OADS in the treatment of type 2 diabetes mellitus (T2DM). The most frequent indication of CTOI is, patients with T2DM who failed to be treated with a maximal dose of OHA, although medical nutrition therapy (MNT) and programmed regular exercise have been perfectly adhered to. Based on clinical experiences another 6 (six) indications of CTOI are listed in this manuscript. For the clinical practice point of view, Formulas 1/3, 5-5, 2-2, 1-1 and Formula 1-2 are provided for the CTOI in the management of patients with T2DM. GLIM can be combined with insulin therapy (f.e. with GLAR) in the treatment of T2DM. Based on the clinical experiences, such a combination can be performed by 3 Methods such as Method- A both GLIM-GLAR administered in the Morning, Method- B GLAR-Morning and GLIM-Evening, and Method- C GLIM-Morning and GLAR-Evening. Conclusions GLIM is 3 gen. sulphonylurea which shows quintuple pleiotropic cardioprotective properties beyond its hypoglycemic effect. GLAR is a human peakless insulin analogue that exhibits a 24-hours action profile (as a basal insulin) with fewer episodes of nocturnal hypoglycemia. Thus, the CTOI GLIM and GLAR combination, may provide for cardioprotective properties. On the basis of clinical experiences, Method-A (by using a prebreakfast injection of insulin GLAR coincides with GLIM) has been proven to be most effective and well tolerated.

Kata kunci

Jaringan kolaborasi para penulis

8 penulis · 16 tautan kepenulisan bersama · 7 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • University of Brawijaya
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Agung Sindu PranotoUniversitas Airlangga1
Hermina NovidaUniversitas Airlangga1
Jongky Hendro PrayitnoAfiliasi tidak diketahui1
Adeodatus Yuda HandayaRumah Sakit Umum Pusat Dr. Sardjito1
Djanggan SargowoUniversity of Brawijaya1
Diana LyrawatiUniversity of Brawijaya1
Mohammad Aris WidodoUniversity of Brawijaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Review Article and Clinical Experience: Insulin Glargine Combined with Oral Agent in T2DM (Clinical Uses of Formulas: 1/3, 5-5, 2-2, 1-1, and 1-2)</dc:title><dc:creator>Askandar Tjokroprawiro</dc:creator><dc:subject>insulin glargine</dc:subject><dc:subject>oral antidiabetic drugs</dc:subject><dc:subject>type 2 diabetes</dc:subject><dc:subject>glimepiride</dc:subject><dc:subject>basal insulin</dc:subject><dc:subject>combination therapy</dc:subject><dc:subject>insulin resistance</dc:subject><dc:subject>atheroprotection</dc:subject><dc:subject>platelet aggregation</dc:subject><dc:subject>PI3K signaling</dc:subject><dc:subject>glycogen synthesis</dc:subject><dc:subject>long-acting insulin analogues</dc:subject><dc:subject>hypoglycemia</dc:subject><dc:subject>diabetic vascular complications</dc:subject><dc:subject>HOMA-IR</dc:subject><dc:description xml:lang="en">A map of oral agents for diabetes (OADS), either at present or in the future should be well recognized. Four of such OADS (glimepiride, glinides, gliclazide, metformin) have claimed showing atheroprotective properties beyond its hypoglycemic or anti- hypoglycemic effects. On the basis of clinical experiences and molecular mechanisms, glimepiride (GLIM) can be summarized having 3B - 3A - 9D properties 3-fold higher rate of Binding to receptor (3B), 3-fold lower Affinity to receptor (3A), and 9-fold faster rate of Dissociation from receptor (9D). These effects (3B-3A-9D) may result in potential therapeutical benefits, including rapid onset (due to 3-fold higher rate of Binding = 3B) and less hypoglycemic events due to lower Affinity (3A) and faster Dissociation (9D). By using therapeutic concentration (in contrast to glibenclamide), GLIM (via PI3-Kinase Pathway) increases insulin - stimulated glycogen synthesis (GS) in human muscle cells (GS effect). In addition, GLIM inhibits platelet aggregation which may in turn have a preventive effect on the development of diabetic vascular complications (more pronounced effect than gliclazide). The ideal basal insulin should ideally have the following six characteristics 1. mimics normal pancreatic basal insulin secretion, 2. long-lasting 24-hour effect, 3. smooth, peakless profile, 4. reproducible and predictable effects, 5. reduces risk of nocturnal hypoglycemia, and 6. once-daily administration. Insulin Glargine (GLAR) is a novel peakless long-acting insulin analogue that is available for clinical use and it has a smooth profile and long, 24-hour duration of action. Thus, GLAR is an improved basal component for combination regimens (Method A, B, and C) with OADS in the treatment of type 2 diabetes mellitus (T2DM). The most frequent indication of CTOI is, patients with T2DM who failed to be treated with a maximal dose of OHA, although medical nutrition therapy (MNT) and programmed regular exercise have been perfectly adhered to. Based on clinical experiences another 6 (six) indications of CTOI are listed in this manuscript. For the clinical practice point of view, Formulas 1/3, 5-5, 2-2, 1-1 and Formula 1-2 are provided for the CTOI in the management of patients with T2DM. GLIM can be combined with insulin therapy (f.e. with GLAR) in the treatment of T2DM. Based on the clinical experiences, such a combination can be performed by 3 Methods such as Method- A both GLIM-GLAR administered in the Morning, Method- B GLAR-Morning and GLIM-Evening, and Method- C GLIM-Morning and GLAR-Evening. Conclusions GLIM is 3 gen. sulphonylurea which shows quintuple pleiotropic cardioprotective properties beyond its hypoglycemic effect. GLAR is a human peakless insulin analogue that exhibits a 24-hours action profile (as a basal insulin) with fewer episodes of nocturnal hypoglycemia. Thus, the CTOI GLIM and GLAR combination, may provide for cardioprotective properties. On the basis of clinical experiences, Method-A (by using a prebreakfast injection of insulin GLAR coincides with GLIM) has been proven to be most effective and well tolerated.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2005-07-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>http://journal.unair.ac.id/filerPDF/FMI-41-3-11.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 41 No 3 (2005)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>